BeiGene Expands Reach of its Innovative BTK Inhibitor with Recent Regulatory Approvals in Latin America
read more...
Oct 14, 2022
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults With CLL
read more...
Oct 12, 2022
BeiGene Announces Positive Topline Results from Final Progression-Free Survival Analysis of BRUKINSA® (zanubrutinib) Compared to IMBRUVICA® (ibrutinib) in Phase 3 Chronic Lymphocytic Leukemia (CLL) Trial
read more...
Sep 19, 2022
NICE Recommends BeiGene’s BRUKINSA® (zanubrutinib) for Patients with Waldenström’s Macroglobulinemia who have had at Least One Treatment
read more...
Sep 19, 2022
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma
read more...
Sep 10, 2022
BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular Cancer
read more...
Sep 07, 2022
BeiGene to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
read more...
Aug 23, 2022
BeiGene Announces Acceptance of 11th Regulatory Submission for PD-1 Inhibitor Tislelizumab in China
read more...
Aug 15, 2022
BeiGene Announces Strategic Alliance with Ontada to Improve U.S. Community Oncology Care
read more...
Aug 09, 2022
BeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab in First-Line Unresectable Hepatocellular Cancer
read more...
Aug 04, 2022
BeiGene Reports Second Quarter 2022 Financial Results
read more...
Jul 14, 2022
BeiGene Provides Regulatory Update on the U.S. Biologics License Application (BLA) for PD-1 Inhibitor Tislelizumab in 2L ESCC
read more...
Jul 13, 2022
BeiGene Appoints Chan Lee as General Counsel
read more...
Jul 06, 2022
BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Novel mRNA Therapies
read more...
Jun 30, 2022
BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab Plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma
read more...
Jun 21, 2022
BeiGene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab
read more...
Jun 13, 2022
BeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets
read more...
Jun 13, 2022
BeiGene Announces PDUFA Goal Date Extension for U.S. sNDA for BRUKINSA for the Treatment of CLL/SLL
read more...
Jun 10, 2022
China NMPA Approves Tislelizumab for Recurrent or Metastatic Nasopharyngeal Cancer
read more...
Jun 10, 2022
BeiGene Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at European Hematology Association 2022 Congress
read more...
